The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia
Adult
Aged
Aged, 80 and over
Area Under Curve
Biomarkers
/ metabolism
C-Reactive Protein
/ metabolism
COVID-19
/ metabolism
Female
Fibrin Fibrinogen Degradation Products
/ metabolism
Humans
Lymphocyte Count
Male
Middle Aged
Mortality
Procalcitonin
/ metabolism
Prognosis
ROC Curve
SARS-CoV-2
Serum Amyloid P-Component
/ metabolism
Troponin
/ metabolism
Young Adult
SARS-CoV-2
COVID-19
pentraxin
disease progression
mortality
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
30 04 2021
30 04 2021
Historique:
received:
03
11
2020
accepted:
12
12
2020
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
8
5
2021
Statut:
epublish
Résumé
The purpose of this study is to evaluate serum pentraxin-3 (PTX-3) levels in Sars-CoV-2 virus infection (COVID-19) patients and to investigate whether PTX-3 predicts the disease prognosis. This study was conducted on 88 confirmed COVID-19 patients who were hospitalized due to symptomatic pneumonia between April 15 and August 15, 2020. The patients were divided into two groups as survived patients and non-survived patients. Both groups were compared according to demographic features, comorbid conditions and measurement of the PTX-3 and other laboratory parameters of the patients. Of 88 patients with COVID-19, 59 (67%) were discharged with complete cure and 29 (33%) resulted in death. 46 (52.3%) of the patients were men. PTX-3 median value (IQR) was 3.66 ng/mL (0.9–27.9) in all patients, 3.3 ng/mL (0.9–27.9) in survivors and 3.91 ng/mL (1.9–23.2) in nonsurvivors which was significantly higher (P = 0.045). As a receiver operating characteristic curve analysis the cut-off value of PTX-3 for predicting mortality in patients was 3.73 with 65% sensitivity and 65% specificity (AUC: 0.646, 95% CI: 0.525– 0.767, P = 0.045). Also, we found significant cut-off values with respect to D-dimer, D-dimer/PTX-3, high-sensitivity troponin, high- sensitivity troponin/PTX-3, lymphocyte, PTX-3/lymphocyte, procalcitonin, procalcitonin/PTX-3, CRP, and CRP/PTX-3 (P < 0.05). In this study, as far as we know, for the first time, we have shown PTX-3 as the new mortality biomarker for COVID-19 disease.
Sections du résumé
Background/aim
The purpose of this study is to evaluate serum pentraxin-3 (PTX-3) levels in Sars-CoV-2 virus infection (COVID-19) patients and to investigate whether PTX-3 predicts the disease prognosis.
Materials and methods
This study was conducted on 88 confirmed COVID-19 patients who were hospitalized due to symptomatic pneumonia between April 15 and August 15, 2020. The patients were divided into two groups as survived patients and non-survived patients. Both groups were compared according to demographic features, comorbid conditions and measurement of the PTX-3 and other laboratory parameters of the patients.
Results
Of 88 patients with COVID-19, 59 (67%) were discharged with complete cure and 29 (33%) resulted in death. 46 (52.3%) of the patients were men. PTX-3 median value (IQR) was 3.66 ng/mL (0.9–27.9) in all patients, 3.3 ng/mL (0.9–27.9) in survivors and 3.91 ng/mL (1.9–23.2) in nonsurvivors which was significantly higher (P = 0.045). As a receiver operating characteristic curve analysis the cut-off value of PTX-3 for predicting mortality in patients was 3.73 with 65% sensitivity and 65% specificity (AUC: 0.646, 95% CI: 0.525– 0.767, P = 0.045). Also, we found significant cut-off values with respect to D-dimer, D-dimer/PTX-3, high-sensitivity troponin, high- sensitivity troponin/PTX-3, lymphocyte, PTX-3/lymphocyte, procalcitonin, procalcitonin/PTX-3, CRP, and CRP/PTX-3 (P < 0.05).
Conclusion
In this study, as far as we know, for the first time, we have shown PTX-3 as the new mortality biomarker for COVID-19 disease.
Identifiants
pubmed: 33315349
doi: 10.3906/sag-2011-32
pmc: PMC8219078
doi:
Substances chimiques
Biomarkers
0
Fibrin Fibrinogen Degradation Products
0
Procalcitonin
0
Serum Amyloid P-Component
0
Troponin
0
fibrin fragment D
0
PTX3 protein
148591-49-5
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
448-453Informations de copyright
This work is licensed under a Creative Commons Attribution 4.0 International License.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Blood. 1996 Mar 1;87(5):1862-72
pubmed: 8634434
PLoS One. 2013;8(1):e53661
pubmed: 23341967
J Med Virol. 2020 Oct;92(10):1875-1883
pubmed: 32441789
Sci Rep. 2019 Apr 29;9(1):6579
pubmed: 31036824
Pathog Glob Health. 2018 Sep;112(6):334-341
pubmed: 30246621
Annu Rev Immunol. 2010;28:157-83
pubmed: 19968561
J Crit Care. 2020 Apr;56:73-79
pubmed: 31855709
Med Mal Infect. 2020 Jun;50(4):332-334
pubmed: 32243911
Clin Chem Lab Med. 1999 Mar;37(3):275-9
pubmed: 10353472
Cell Syst. 2020 Jul 22;11(1):11-24.e4
pubmed: 32619549
J Clin Immunol. 2008 Jan;28(1):1-13
pubmed: 17828584
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175
pubmed: 32615866
Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1039-49
pubmed: 17277044
Clin Chim Acta. 2020 Nov;510:665-670
pubmed: 32828732
Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399
pubmed: 32503382
J Infect Dis. 1998 Mar;177(3):778-82
pubmed: 9498463
BMC Infect Dis. 2019 Nov 12;19(1):968
pubmed: 31718563